Diabetes is a serious illness that leads to a number of microvascular complications, including diabetic neuropathy, diabetic nephropathy and diabetic retinopathy. In addition, a large number of type 2 diabetic patients develop non-alcoholic steatohepatitis (NASH). Emerging science and clinical evidence strongly implicate certain pathways in the pathogenesis of some of the metabolic complications. We are developing key biologic molecules that can help us interrogate these pathways and assess their therapeutic potential.